Developer docs
API playgroundTry for free, no card

Search company profiles

GlucoModicum

Full company profile

uuid0002gfd

Namestring
GlucoModicum
Legal namestring
GlucoModicum
Company typeenum
Private
Founded yearint
2018
Descriptiontext

GlucoModicum is a Finnish health technology company founded in 2018 and headquartered in Helsinki, developing Sofio™, a needle-free continuous glucose monitoring sensor based on proprietary magneto-hydrodynamic (MHD) technology. The device draws a micro-sample through the skin without needles, enabling single-day glucose monitoring for people with diabetes, and has been validated in clinical studies involving over 2,000 participants. The technology represents a first-in-class architectural departure from existing needle-based CGM approaches, directly addressing pain, discomfort, and compliance barriers associated with traditional glucose monitoring.

The company has partnered with Mpac Lambert to design and build an automated manufacturing line capable of sub-second cycle times with an initial annual capacity of 21 million units, expandable through additional modules. This two-year industrial proof-of-principle effort positions GlucoModicum to transition from lab-scale demonstration to commercial production for global distribution. Sofio was unveiled in December 2025 in Helsinki, with the manufacturing partnership formalised in January 2026.

GlucoModicum operates a hardware-based B2B medical device business model, targeting healthcare providers and patients with diabetes globally. Revenue is expected to be generated through sales of the Sofio device enabled by its global distribution partnership, though specific pricing, customer relationships, and revenue figures are not publicly disclosed. The company is led by co-founders Alejandro García Pérez (CTO) and Jokke Mäki (Managing Director), with disclosed funding of approximately $3 million from the European Innovation Council in 2021.

Short descriptiontext

GlucoModicum is a Finnish health technology company that develops Sofio™, the world's first needle-free glucose monitoring sensor using magneto-hydrodynamic (MHD) technology, serving people with diabetes and healthcare providers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
needle-free glucose monitoring, continuous glucose monitoring, medical device manufacturing, diabetes care technology, magnetohydrodynamic sensors
Industry1 code
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Continuous Glucose Monitoring Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Sofio Device Sales
TypeHardware Sales
Description

Revenue generated from the sale of the Sofio needle-free glucose monitoring sensor, a medical device for single-day glucose monitoring. The manufacturing partnership with Mpac Lambert enables commercial-scale production for global distribution.

globenewswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Sofio
Description

The world's first needle-free glucose monitoring device using magnetohydrodynamic (MHD) technology that measures glucose levels by drawing a micro-sample through the skin without needles.

globenewswire.com
Core offering1 text field

GlucoModicum develops and manufactures Sofio, a needle-free continuous glucose monitoring sensor that uses proprietary magnetohydrodynamic (MHD) technology to draw a micro-sample through the skin and enable single-day glucose monitoring. The device is targeted at people with diabetes and is produced via an automated manufacturing line (built with partner Mpac Lambert) with an initial capacity of 21 million units per year for global commercial distribution.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

GlucoModicum is a Finnish health technology company that offers a single unified product: Sofio™, the world's first needle-free glucose monitoring sensor. Sofio™ uses proprietary magneto-hydrodynamic (MHD) technology to draw micro-samples through the skin without needles, enabling non-invasive single-day glucose monitoring. The product is produced via an automated manufacturing line developed with partner Mpac Lambert, with an initial capacity of approximately 21 million units per year.

Product and service1 record
1Sofio
CategoryContinuous Glucose Monitoring Devices
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Mpac Lambert partnered with GlucoModicum to design and build a first-of-its-kind automated manufacturing line for Sofio, GlucoModicum's needle-free glucose monitoring sensor. The production system achieves sub-second cycle times with an initial capacity of 21 million units per year and can be expanded by adding additional modules. The collaboration aims to transition Sofio from lab-scale demonstration to commercial production for global distribution, making needle-free glucose tracking more widely accessible.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Markets Eversense, the only long-term implantable CGM (180-day sensor). Comparable as a smaller-cap glucose monitoring innovator with a differentiated architecture targeting the same diabetes patient population.

TypeDirect peer
Description

Global market leader in continuous glucose monitoring (CGM) sensors (G6, G7). Directly comparable as a CGM device maker targeting diabetes patients and clinicians, though GlucoModicum's needle-free MHD approach is a category-defining differentiation rather than a like-for-like device.

TypeEmerging player
Description

Developing a non-invasive, radio-frequency-based glucose monitor (KnowU). Closely comparable to GlucoModicum as an emerging player pursuing needle-free / non-invasive glucose measurement using a fundamentally different physical mechanism.

TypeBroad incumbent
Description

Major incumbent in blood glucose monitoring (Accu-Chek) historically dominant in BGM strips and now expanding into CGM. Comparable as a broad incumbent in glucose monitoring devices serving diabetes patients worldwide.

TypeEmerging player
Description

Developing a non-invasive continuous glucose monitoring wearable (Lief). Comparable as an emerging player in needle-free CGM, though at an earlier commercial stage than GlucoModicum.

TypeBroad incumbent
Description

Spun out of Bayer Diabetes Care, markets the CONTOUR line of blood glucose meters. Comparable as an established glucose monitoring incumbent with global distribution, though focused on BGM strips rather than needle-free CGM.

TypeEmerging player
Description

Early-stage UK developer of a non-invasive, wearable continuous blood glucose monitor. Comparable as an emerging player in needle-free / non-invasive glucose sensing targeting the same diabetes use case as GlucoModicum's Sofio.

TypeBroad incumbent
Description

Sells the Guardian CGM system alongside its insulin pump portfolio (MiniMed). Comparable as a major medtech incumbent in diabetes care devices, with overlapping customers (endocrinologists and insulin-using patients) but a much wider product portfolio.

9Abbott
TypeBroad incumbent
Description

Markets the FreeStyle Libre family of CGM sensors, the dominant global CGM franchise by volume. Comparable as a glucose monitoring medical device incumbent serving people with diabetes, though Abbott is a diversified diagnostics and devices giant with a much broader portfolio.

TypeEmerging player
Description

Developing meta-optical sensing technology including non-invasive glucose monitoring applications. Comparable as an emerging player exploring novel physical mechanisms for glucose/biomarker sensing, with overlapping R&D ambition though a different sensing modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GlucoModicum

Continuous Glucose Monitoring Devicesglucomodicum.com

GlucoModicum is a Finnish health technology company that develops Sofio™, the world's first needle-free glucose monitoring sensor using magneto-hydrodynamic (MHD) technology, serving people with diabetes and healthcare providers globally.

What GlucoModicum does

GlucoModicum is a Finnish health technology company founded in 2018 and headquartered in Helsinki, developing Sofio™, a needle-free continuous glucose monitoring sensor based on proprietary magneto-hydrodynamic (MHD) technology. The device draws a micro-sample through the skin without needles, enabling single-day glucose monitoring for people with diabetes, and has been validated in clinical studies involving over 2,000 participants. The technology represents a first-in-class architectural departure from existing needle-based CGM approaches, directly addressing pain, discomfort, and compliance barriers associated with traditional glucose monitoring.

The company has partnered with Mpac Lambert to design and build an automated manufacturing line capable of sub-second cycle times with an initial annual capacity of 21 million units, expandable through additional modules. This two-year industrial proof-of-principle effort positions GlucoModicum to transition from lab-scale demonstration to commercial production for global distribution. Sofio was unveiled in December 2025 in Helsinki, with the manufacturing partnership formalised in January 2026.

GlucoModicum operates a hardware-based B2B medical device business model, targeting healthcare providers and patients with diabetes globally. Revenue is expected to be generated through sales of the Sofio device enabled by its global distribution partnership, though specific pricing, customer relationships, and revenue figures are not publicly disclosed. The company is led by co-founders Alejandro García Pérez (CTO) and Jokke Mäki (Managing Director), with disclosed funding of approximately $3 million from the European Innovation Council in 2021.

GlucoModicum firmographics

Firmographics
Name
GlucoModicum
Legal name
GlucoModicum
Website
https://glucomodicum.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
GlucoModicum is a Finnish health technology company that develops Sofio™, the world's first needle-free glucose monitoring sensor using magneto-hydrodynamic (MHD) technology, serving people with diabetes and healthcare providers globally.
Ownership category
akta.pro rank

GlucoModicum industry classification

Industry
Product category
Continuous Glucose Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Needle-free glucose monitoring
  • Continuous glucose monitoring
  • Medical device manufacturing
  • Diabetes care technology
  • Magnetohydrodynamic sensors

Where GlucoModicum is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

GlucoModicum business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Sofio Device Sales: Revenue generated from the sale of the Sofio needle-free glucose monitoring sensor, a medical device for single-day glucose monitoring. The manufacturing partnership with Mpac Lambert enables commercial-scale production for global distribution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

GlucoModicum product offering

Product offering

Core offering

GlucoModicum develops and manufactures Sofio, a needle-free continuous glucose monitoring sensor that uses proprietary magnetohydrodynamic (MHD) technology to draw a micro-sample through the skin and enable single-day glucose monitoring. The device is targeted at people with diabetes and is produced via an automated manufacturing line (built with partner Mpac Lambert) with an initial capacity of 21 million units per year for global commercial distribution.

Product overview

GlucoModicum is a Finnish health technology company that offers a single unified product: Sofio™, the world's first needle-free glucose monitoring sensor. Sofio™ uses proprietary magneto-hydrodynamic (MHD) technology to draw micro-samples through the skin without needles, enabling non-invasive single-day glucose monitoring. The product is produced via an automated manufacturing line developed with partner Mpac Lambert, with an initial capacity of approximately 21 million units per year.

Differentiator

Problem solved

Functional benefit

Brands

  • Sofio: The world's first needle-free glucose monitoring device using magnetohydrodynamic (MHD) technology that measures glucose levels by drawing a micro-sample through the skin without needles.

Products and services

  • Sofio

Companies that use GlucoModicum

Customer profile

Segments2 records

Ideal customer profiles2 records

GlucoModicum technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

GlucoModicum partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mpac LambertcoreStrategic or Co-development Partner · 29 January 2026Mpac Lambert partnered with GlucoModicum to design and build a first-of-its-kind automated manufacturing line for Sofio, GlucoModicum's needle-free glucose monitoring sensor. The production system achieves sub-second cycle times with an initial capacity of 21 million units per year and can be expanded by adding additional modules. The collaboration aims to transition Sofio from lab-scale demonstration to commercial production for global distribution, making needle-free glucose tracking more widely accessible.

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

GlucoModicum competitors and assessment

Company assessment

Emerging players

  • Senseonics: Markets Eversense, the only long-term implantable CGM (180-day sensor). Comparable as a smaller-cap glucose monitoring innovator with a differentiated architecture targeting the same diabetes patient population.
  • Know Labs: Developing a non-invasive, radio-frequency-based glucose monitor (KnowU). Closely comparable to GlucoModicum as an emerging player pursuing needle-free / non-invasive glucose measurement using a fundamentally different physical mechanism.
  • LifePlus: Developing a non-invasive continuous glucose monitoring wearable (Lief). Comparable as an emerging player in needle-free CGM, though at an earlier commercial stage than GlucoModicum.
  • Afon Technology: Early-stage UK developer of a non-invasive, wearable continuous blood glucose monitor. Comparable as an emerging player in needle-free / non-invasive glucose sensing targeting the same diabetes use case as GlucoModicum's Sofio.
  • Metamaterial Inc. Developing meta-optical sensing technology including non-invasive glucose monitoring applications. Comparable as an emerging player exploring novel physical mechanisms for glucose/biomarker sensing, with overlapping R&D ambition though a different sensing modality.

Direct peers

  • Dexcom: Global market leader in continuous glucose monitoring (CGM) sensors (G6, G7). Directly comparable as a CGM device maker targeting diabetes patients and clinicians, though GlucoModicum's needle-free MHD approach is a category-defining differentiation rather than a like-for-like device.

Broad incumbents

  • Roche Diabetes Care: Major incumbent in blood glucose monitoring (Accu-Chek) historically dominant in BGM strips and now expanding into CGM. Comparable as a broad incumbent in glucose monitoring devices serving diabetes patients worldwide.
  • Ascensia Diabetes Care: Spun out of Bayer Diabetes Care, markets the CONTOUR line of blood glucose meters. Comparable as an established glucose monitoring incumbent with global distribution, though focused on BGM strips rather than needle-free CGM.
  • Medtronic: Sells the Guardian CGM system alongside its insulin pump portfolio (MiniMed). Comparable as a major medtech incumbent in diabetes care devices, with overlapping customers (endocrinologists and insulin-using patients) but a much wider product portfolio.
  • Abbott: Markets the FreeStyle Libre family of CGM sensors, the dominant global CGM franchise by volume. Comparable as a glucose monitoring medical device incumbent serving people with diabetes, though Abbott is a diversified diagnostics and devices giant with a much broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

GlucoModicum social profiles

Digital presence

GlucoModicum financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GlucoModicum leadership team

Management profile

Number of profiles

Profiles2 records

GlucoModicum funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GlucoModicum M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlucoModicum

What does GlucoModicum do?

GlucoModicum develops and manufactures Sofio, a needle-free continuous glucose monitoring sensor that uses proprietary magnetohydrodynamic (MHD) technology to draw a micro-sample through the skin and enable single-day glucose monitoring. The device is targeted at people with diabetes and is produced via an automated manufacturing line (built with partner Mpac Lambert) with an initial capacity of 21 million units per year for global commercial distribution.

Is GlucoModicum a public or private company?

GlucoModicum is a private company. It is classified as venture growth investor backed and is currently operating.

When was GlucoModicum founded?

GlucoModicum was founded in 2018. It employs 51 to 100 people.

Where is GlucoModicum based?

GlucoModicum is headquartered in Helsinki, Finland, in the Europe region.

How does GlucoModicum make money?

One revenue line is on record: sofio Device Sales.

Who are GlucoModicum's main competitors?

Emerging players on record are Senseonics, Know Labs, LifePlus, Afon Technology and Metamaterial Inc.. Dexcom is listed as a direct peer. Broad incumbents are Roche Diabetes Care, Ascensia Diabetes Care, Medtronic and Abbott.

Does GlucoModicum have an API?

No public API is recorded for GlucoModicum.

What industry is GlucoModicum in?

GlucoModicum's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Hattiesburg AmericanMpac Lambert Partners with GlucoModicum to Deliver Scalable Automation for Needle-Free Glucose Monitoring SensorMpac Lambert has partnered with GlucoModicum to design and build a first-of-its-kind automated manufacturing line for Sofio, GlucoModicum's needle-free glucose monitoring sensor. The production system achieves sub-second cycle times with an initial capacity of 21 million units per year and can be expanded by adding additional modules. The collaboration aims to transition Sofio from lab-scale demonstration to commercial production for global distribution, making needle-free glucose tracking more widely accessible.The News StarMpac Lambert Partners with GlucoModicum to Deliver Scalable Automation for Needle-Free Glucose Monitoring SensorMpac Lambert has partnered with GlucoModicum to design and build a first-of-its-kind automated manufacturing line for Sofio, a needle-free glucose monitoring sensor. The production system achieves sub-second cycle times with an initial capacity of approximately 21 million units per year, expandable through additional modules. The collaboration enables GlucoModicum to scale from lab-scale demonstration to commercial production for global distribution of the MHD-based monitoring device.GlobeNewswireNewly published research further validates GlucoModicum’s path to high-precision, non-invasive glucose monitorGlucoModicum published a peer-reviewed study in Biosensors and Bioelectronics on ultrasensitive electrochemical glucose biosensors, detailing up to 100× sensitivity amplification. The research underpins Sofio, the company's needle-free glucose monitor, and supports its manufacturing and market readiness.The Desert SunMpac Lambert Partners with GlucoModicum to Deliver Scalable Automation for Needle-Free Glucose Monitoring SensorMpac Lambert has partnered with GlucoModicum to design and build an automated manufacturing line for Sofio, a needle-free glucose monitoring sensor that uses magnetohydrodynamic technology to measure glucose levels without needles. The production system achieves sub-second cycle times and maintains medical-grade precision while delivering an initial annual capacity of approximately 21 million units, with options to expand further. The two companies spent two years conducting industrial-scale proof-of-principle work before construction, producing tens of thousands of pilot units to validate the manufacturing platform ahead of global commercial rollout.Weekly VoiceMpac Lambert Partners with GlucoModicum to Deliver Scalable Automation for Needle-Free Glucose Monitoring SensorMpac Lambert has partnered with GlucoModicum to design and build a first-of-its-kind automated manufacturing line for Sofio, a needle-free glucose monitoring sensor using magnetohydrodynamic technology. The production system achieves sub-second cycle time with an initial capacity of approximately 21 million units annually, expandable through additional modules. The collaboration enables GlucoModicum to transition Sofio from lab-scale manual and semi-automated production to high-volume commercial manufacturing for global distribution.GlobeNewswireGlucoModicum unveils Sofio™, the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD)Finnish medical technology company GlucoModicum unveiled Sofio™, claimed to be the world's first needle-free glucose monitor using magnetohydrodynamics (MHD) technology to draw interstitial fluid through the skin for glucose measurement. The device, featuring a rechargeable transmitter and single-day replaceable sensor, completed extensive clinical studies with over 2,000 participants demonstrating accuracy in line with regulatory expectations. The company is progressing through European regulatory pathways toward CE marking and advancing its U.S. FDA pathway, with commercial updates expected in 2026.GlobeNewswireGlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market LaunchGlucoModicum announced positive clinical results from its needle-free CGM study, which included 646 participant visits and achieved an 11.5% MARD. The company has completed an ISO 13485 audit and received FIMEA authorization, with results to be reported to FIMEA in H2 2025.GlobeNewswireTalisman needle-free CGM demonstrates strong correlation to blood glucose in clinical studies and moves towards large volume manufacturingGlucoModicum reported strong correlation between its Talisman needle-free CGM and blood glucose in a clinical study with over 100 participants. The company plans mass manufacturing, with a first automation line producing 21 million sensors annually and device ramp-up to 100,000 units. It expects device pilot production by end of 2024 and sensor pilot in 2025.GlobeNewswireTalisman needle-free CGM demonstrates strong correlation to blood glucose in clinical studies and moves towards large volume manufacturingGlucoModicum reported strong correlation between its Talisman needle-free CGM and blood glucose in a clinical study with over 100 participants. The company plans large-volume manufacturing, with a first automation line producing 21 million sensors annually and device pilot production in 2024.